Related Experiment Video
Updated: Jul 19, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine
Daniel J Isaacman1, Mark A Fletcher, Bernard Fritzell
1Global Medical Affairs, Wyeth Pharmaceuticals, 500 Arcola Road, Collegeville, PA 19426, USA. ISAACMD@wyeth.com
Insights
Widespread use of Prevnar (pneumococcal conjugate vaccine; PCV7) indirectly protects unvaccinated individuals by reducing disease transmission. This finding supports the cost-effectiveness of vaccination programs for invasive pneumococcal disease (IPD).
Area of Science:
- Public Health
- Vaccinology
- Epidemiology
Background:
- Prevnar (pneumococcal conjugate vaccine; PCV7) targets invasive pneumococcal disease (IPD) caused by specific serotypes.
- Indirect protection occurs when vaccination reduces pathogen transmission, benefiting unvaccinated populations.
- Infants and young children are key reservoirs for vaccine-type pneumococcal bacteria.
Purpose of the Study:
- To review published data on IPD incidence in unvaccinated individuals.
- To assess the indirect protection conferred by universal PCV7 vaccination programs.
- To inform cost-benefit analyses of vaccination strategies.
Main Methods:
- Systematic review of published reports.
- Analysis of IPD incidence data from 1998-2005.
- Focus on non-immunised populations in countries with PCV7 programs.
Main Results:
- Non-immunised individuals demonstrated a benefit from indirect protection.
- Widespread PCV7 vaccination led to decreased transmission of vaccine serotypes.
- This indirect effect enhances the economic justification for vaccination programs.
Conclusions:
- Universal PCV7 vaccination provides significant indirect protection to unvaccinated individuals.
- The findings support the value of PCV7 in public health interventions.
- Ongoing surveillance is crucial for monitoring non-vaccine type IPD, especially in high-risk groups.
Abstract:
Prevnar (heptavalent pneumococcal conjugate vaccine; PCV7) provides protection against invasive pneumococcal disease (IPD) caused by vaccine serotypes. Indirect protection of non-immunised individuals may be the consequence of decreased transmission of vaccine serotypes, generally carried in the nasopharynx of infants and young children. This review summarises published reports of IPD incidence (1998-2005) among non-immunised individuals in countries with universal PCV7 immunisation. Findings suggest that non-immunised individuals benefit from indirect protection following widespread vaccination, enhancing cost-benefit evaluations of vaccination programs. Continued surveillance will be important, to follow future changes associated with non-vaccine type IPD, particularly among individuals with medical co-morbidities that may put them at higher risk of disease.
Related Concept Videos
Respiratory Syncytial Virus Disease
Vaccinations
Poliomyelitis
Smallpox
Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Teratogenicity

